Gram Scientific ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.6% 1.6% 1.6% 1.6% 1.6%  
Bankruptcy risk  0.0% 0.0% 14.8% 3.3% 1.4%  
Credit score (0-100)  0 0 13 54 78  
Credit rating  N/A N/A BB BBB A  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 493.2  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 49,559 75,065  
EBITDA  0.0 0.0 0.0 -744 19,336  
EBIT  0.0 0.0 0.0 42,253 19,232  
Pre-tax profit (PTP)  0.0 0.0 -2.1 42,522.9 19,210.0  
Net earnings  0.0 0.0 -2.1 33,124.7 14,837.2  
Pre-tax profit without non-rec. items  0.0 0.0 -2.1 42,523 19,210  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 1,173  
Shareholders equity total  0.0 0.0 97.9 41,123 47,960  
Interest-bearing liabilities  0.0 0.0 0.0 82.9 128  
Balance sheet total (assets)  0.0 0.0 97.9 69,512 73,775  

Net Debt  0.0 0.0 -37.9 -24,719 -18,017  
 
See the entire balance sheet

Volume 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 49,559 75,065  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 51.5%  
Employees  0 0 0 106 120  
Employee growth %  0.0% 0.0% 0.0% 0.0% 13.2%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 98 69,512 73,775  
Balance sheet change%  0.0% 0.0% 0.0% 70,894.7% 6.1%  
Added value  0.0 0.0 0.0 42,252.5 19,336.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 1,069  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 1.0 2.0  

Profitability 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 85.3% 25.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% 123.6% 27.7%  
ROI %  0.0% 0.0% 0.0% 188.5% 41.0%  
ROE %  0.0% 0.0% -2.1% 160.7% 33.3%  

Solidity 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 0.0% 100.0% 59.2% 65.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 3,321.6% -93.2%  
Gearing %  0.0% 0.0% 0.0% 0.2% 0.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 1,184.7% 597.7%  

Liquidity 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 0.0 0.0 1.7 1.7  
Current Ratio  0.0 0.0 0.0 2.9 3.2  
Cash and cash equivalent  0.0 0.0 37.9 24,802.3 18,145.0  

Capital use efficiency 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 97.9 44,512.0 49,083.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 399 161  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -7 161  
EBIT / employee  0 0 0 399 160  
Net earnings / employee  0 0 0 312 124